Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2014

View Archived Issues

Nuclear export inhibition reduces hepatocellular carcinoma proliferation in preclinical models

Horizon CombinatoRx contracted to profile oncology asset

NIH provides grant support for pulmonary research program

Aduro BioTech expands lung cancer collaboration with Johnson & Johnson and Janssen

AstraZeneca forms new collaborations with the University of Cambridge

Moderna Therapeutics forms strategic partnership with KI and KUH

Cardiorentis to incorporate Roche in vitro diagnostic tests into phase III study of ularitide

Ampio Pharmaceuticals provides update on multiple-injection studies of Ampion

Chimerix updates pipeline progress

Serotonin receptor polymorphisms studied in patients with refractory depression

Phase II cystic fibrosis candidate NVP-QBW-251 data reported

Phase I results for the new prolonged-duration local anesthetic, neosaxitoxin

Piramal patents EZH2 inhibitors

Lilly describes bifunctional fusion protein for diabetes, obesity and dyslipidemia

Australian institute awarded grant funding for cancer and immune disorders research

Merck & Co. patent describes development of SYK inhibitors

Bayer Schering Pharma prepares and tests BUB1 inhibitors

Results from PIONEER II trial of adalimumab in the treatment of hidradenitis suppurativa

Imbruvica approved in Europe for two blood cancers

Janssen applies for approval of additional indication for Velcade in Japan

Astellas and CoMentis to end beta-secretase inhibitor collaboration agreement

Interim analysis of PUNCH-CD trial results demonstrate safety and efficacy of RBX-2660

Amicus releases further data from phase III study of migalastat in Fabry's disease

Roche reports pipeline progress of third quarter 2014

Genervon completes analysis of GM-6 data from phase II PD and ALS trials

R-Tech Ueno begins phase I trial of anti-inflammatory candidate RTU-1096

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...